onr:"swepub:oai:DiVA.org:uu-172441"
Search: onr:"swepub:oai:DiVA.org:uu-172441" > Activity ex vivo of...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Cashin, Peter H,1984-Uppsala universitet,Kolorektalkirurgi,Peritoneal Carcinomatos Forskargrupp (author)
Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
- Article/chapterEnglish2013
Publisher, publication year, extent ...
- 2013-09-24
- Springer Science and Business Media LLC,2013
- electronicrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-172441
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172441URI
- https://doi.org/10.1186/1471-2407-13-435DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Background: The optimal choice of cytotoxic drugs for intraperitoneal chemotherapy (IPC) in conjunction with cytoreductive surgery (CRS) for treatment of peritoneal carcinomatosis(PC) is poorly defined. We investigated drug sensitivity ex vivo in patient samples of various PC tumor types and correlated clinical outcome to drug sensitivity within the subset of PC fromcolorectal cancer (CRC). Methods: PC tissue samples (n = 174) from mesothelioma, pseudomyxoma peritonei (PMP), ovarian cancer, CRC or appendix cancer were analyzed ex vivo for sensitivity to oxaliplatin, cisplatin, mitomycin C, melphalan, irinotecan, docetaxel, doxorubicin and 5-FU. Clinicopathological variables and outcome data were collected for the CRC subset. Results: Mesothelioma and ovarian cancer were generally more drug sensitive than CRC, appendix cancer and PMP. Oxaliplatin showed the most favorable ratio between achievable IPC concentration and ex vivo drug sensitivity. Drug sensitivity in CRC varied considerably between individual samples. Ex vivo drug sensitivity did not obviously correlate to time-to-progression (TTP) in individual patients. Conclusions: Drug-sensitivity varies considerably between PC diagnoses and individual patients arguing for individualized therapy in IPC rather than standard diagnosis-specific therapy. However, in the current paradigm of treatment according to diagnosis, oxaliplatin is seemingly the preferred drug for IPC from a drug sensitivity and concentration perspective. Inthe CRC subset, analysis of correlation between ex vivo drug sensitivity and TTP was inconclusive due to the heterogeneous nature of the data.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Mahteme, HaileUppsala universitet,Kolorektalkirurgi(Swepub:uu)hailmaht (author)
- Graf, WilhelmUppsala universitet,Kolorektalkirurgi(Swepub:uu)wilhgraf (author)
- Karlsson, HenningUppsala universitet,Klinisk farmakologi(Swepub:uu)henka962 (author)
- Larsson, RolfUppsala universitet,Klinisk farmakologi(Swepub:uu)rolflars (author)
- Nygren, PeterUppsala universitet,Enheten för onkologi(Swepub:uu)peterng (author)
- Uppsala universitetKolorektalkirurgi (creator_code:org_t)
Related titles
- In:BMC Cancer: Springer Science and Business Media LLC13, s. 435-1471-2407
Internet link
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Cashin, Peter H, ...
- Mahteme, Haile
- Graf, Wilhelm
- Karlsson, Hennin ...
- Larsson, Rolf
- Nygren, Peter
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- BMC Cancer
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
